Leiden chemists, together with colleagues at the University of York (UK) and Technion (Israel) have discovered a small, sugar-like molecule that maintains the integrity of tissue around a tumour during cancer. This molecule prevents tumour cells from spreading from the primary cancer site to colonise…

Promotores: Prof.dr. P.C.W. Hogendoorn & Prof.dr. H.P. Spaink, Co-promotor: Dr. B.E. Snaar-Jagalska

Bet v1, the major allergen in birch pollen, is one of the main causes of allergies such as asthma and rhino-conjunctivitis. Additionally it is the main cause of birch pollen allergy in humans.

In the research programme Drug Discovery & Safety, we are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.

Dr. Leila Akkari has been appointed professor by special appointment at the Leiden Institute of Chemistry (LIC) as per 15 December 2025. Her chair, entitled Cancer-Immune Interactions, has been established by the Netherlands Cancer Institute (NKI), where Dr. Akkari works as a researcher.

The Leiden Institute of Physics has been awarded three out of twelve available grants from the FOM Projectruimte. Principal Investigators Milan Allan, Stefan Semrau and Carlo Beenakker all receive around 400,000 euro for their research.

Chemotherapy that does nothing until you irradiate it with light. Sylvestre Bonnet receives a Vici grant of 1.5 million euros for the development of this treatment. The Leiden chemist wants to build a new molecule to fight tumours that are at the time still difficult to treat.

Leiden has a long history in the treatment of blood cell cancer. Research to find better therapies never stands still. One of the potential treatments currently being worked on is a ‘living medicine’.

Lecture

Treatment and care for cancer patients is becoming increasingly advanced. For example, surgeons can now perform operations with much greater precision, and therapeutic vaccines are being developed to prompt the patient’s immune system to fight cancer. Work is also being done on better early diagnostics,…

Key publications of the Cancer Drug Target Discovery group

PhD defence

Dutch researchers are joining forces to conduct research together with a series of societal partners to keep the biological clock healthy in our modern 24-hour society. The BioClock consortium will receive a research grant of no less than 9.7 million euros for this. It is one of the projects that receive…

Discovery of metastasis promoting candidate drug targets

An overview of the research at the Cancer Dug Target Discovery group.

PhD defence

More and more medicines are becoming available that target a tumour’s specific traits. The use of chemotherapy is continually undergoing improvement.

Pathways of toxicity

What is the most effective way to eliminate tumour cells? The DNA repair mechanism could play an important role in increasing the effectiveness of chemotherapy in the fight against cancerous cells. If we are to influence this mechanism, we need fundamental knowledge about how the mechanism works.

PhD defence

Coordination chemistry is the chemistry of metal atoms

The research conducted at the Leiden Academic Centre for Drug Research is clustered within the divisions of BioTherapeutics, Cell Systems and Drug Safety, Medicinal Chemistry and Systems Pharmacology and Pharmacy, and the Metabolomics and Analytics Centre.

Helping cancer patients with treatment choices.

Pancreatic ductal adenocarcinoma (PDAC) is the deadliest common cancer, with only 8% of patients surviving for five years. One reason for this poor outcome is that current chemotherapy treatments are highly toxic, often leaving patients too sick to receive treatment or forcing doctors to lower the dose…

Maria Yazdanbakhsh, Professor of Parasitology at the Leiden University Medical Centre (LUMC), has been awarded an ERC Advanced Grant of 2.5 million euros. She will investigate why people in Africa and Southeast Asia respond less to certain vaccines than Europeans. Her goal is to find a solution for…

PhD defence

This joint two-year parttime Master's programme will equip you with the necessary competences to play a key role in the emerging field of transfusion medicine. Its current concept includes both the transfusion of classical blood components and hematopoietic transplants, but also cellular (e.g. as immunotherapy)…

We study how communication can heal and harm when patients are confronted with an illness. Most of our studies focus on serious illnesses such as advanced cancer. Communication lies at the heart of medicine, yet we do not always know which specific communication helps patients. Moreover, many complaints…

KNAW has elected eighteen new members, including two professors at Leiden University and one who studied and obtained his PhD in Leiden. The New Academy members will be installed at a later date this year.

PhD defence

PhD defence

PhD defence

To get a feeling of how we operate at LED3 when it comes to Early Drug Discovery, please browse through our case studies. When you select a case study you’ll find relevant contacts.

Our research in the area of safety sciences aims to increase the mechanistic understanding of cellular toxicity of drugs and, in a broader sense, chemicals.

Molecular Physiology is a research group at the Leiden Institute of Chemistry dedicated to the design, synthesis and application of chemical tools to study important biological and biomedical questions. The group is headed by Prof. Dr. Mario van der Stelt and includes the research lines of Assistant…

Promotores: B. van de Water; P. Hogendoorn; J. Bovée Co-Promotor: E.H.J. Danen

Animal Sciences’ contribution to the Bioactive Molecules research theme includes research on molecules from natural sources, such as plants, insects, and snake venom, with the aim to identify novel anti-cancer, anti-inflammatory, anti-microbial, and anti-diabetic agents.

Promotor: T. Schmidt, Co-Promotor: B.E. Snaar-Jagalska

Inactivating mutations in BRCA1 or BRCA2 genes predispose to several types of cancer.

Source: Nature Biotechnology, Volume 2014, Issue June (2014)

Glycosidases (GHs) are enzymes responsible for the degradation of carbohydrates and play many roles in human health and pathophysiology. Often, abnormal levels of glycosidase activity are markedly linked to human pathologies.

Animal Sciences’ contributions to the Development & Disease research theme include the mechanisms and evolution of embryonic development, the development of cognitive mechanisms, and animal models for understanding mechanisms of human disease.

Cell adhesion signaling

Overkleeft

These awards honour researchers who turn scientific insight into real-world impact. From master’s students to postdocs, they highlight exceptional work in life sciences, health sciences, biotech, or environmental health sciences with data science at the core. Meet the 2025 winners.

If you are interested in Life Science and you are looking for a programme with ample opportunities to put together your own study path, our Life Science and Technology programme is the right choice. The programme focuses on societal problems at the molecular and cellular level.

Metal-containing molecules combine geometrical features and a reactivity that are inherently different from that of organic molecules. My research focuses on light-activatable metal-based anticancer drugs and metal-functionalized liposomes. Light is a very selective way to activate photosensitive drugs…

The majority (80%) of e-waste generated globally are recycled informally in developing countries.

Improving health, enhancing well-being and reducing health disparities across society.